IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

Zacks10-16

Immuneering Corporation IMRX announced that the FDA has granted orphan drug designation to its lead product candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares of the company were up ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476945329?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","is_english":true,"pubTime":"2024-10-16 22:24","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2476945329","market":"us","top_or_hot":-1,"title":"IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug","media":"Zacks","content":"<div>\n<p>Immuneering Corporation IMRX announced that the FDA has granted orphan drug designation to its lead product candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares of the company were up ...</p>\n\n<a href=\"https://finance.yahoo.com/news/imrx-stock-fdas-orphan-drug-142400084.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-16 22:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/imrx-stock-fdas-orphan-drug-142400084.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immuneering Corporation IMRX announced that the FDA has granted orphan drug designation to its lead product candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares of the company were up ...</p>\n\n<a href=\"https://finance.yahoo.com/news/imrx-stock-fdas-orphan-drug-142400084.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALNY","symbol_name":"阿尔尼拉姆制药公司","start_time":0,"source_url":"https://finance.yahoo.com/news/imrx-stock-fdas-orphan-drug-142400084.html","article_id":"2476945329","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476945329","pubTimestamp":1729088640,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Immuneering Corporation IMRX announced that the FDA has granted orphan drug designation to its lead product candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares of the company were up 15.5% on Oct. 15 following the announcement of the news.The FDA grants Orphan Drug Designation to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. The Orphan Drug Designation makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies as well as exemptions from certain FDA application fees.IMM-1-104 was earlier granted the FDA’s Fast Track designation in the United States for the treatment of first- and second-line pancreatic cancer.Year to date, shares of Immuneering have plunged 68.6% compared with the industry’s decrease of 1.8%.Last month, the company announced positive early response data from the first five patients of an ongoin","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALNY":"阿尔尼拉姆制药公司","IMRX":"Immuneering Corp","BK4563":"昨日强势股","BK4548":"巴美列捷福持仓","ANIP":"ANI Pharmaceuticals, Inc.","BK4539":"次新股","VYGR":"Voyager Therapeutics Inc","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4007":"制药"},"translate_title":"IMRX储备FDA胰腺癌药物孤儿药标签","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1,"ANIP":1,"IMRX":1,"VYGR":1},"content_text":"Immuneering Corporation IMRX announced that the FDA has granted orphan drug designation to its lead product candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares of the company were up 15.5% on Oct. 15 following the announcement of the news.\nThe FDA grants Orphan Drug Designation to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. The Orphan Drug Designation makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies as well as exemptions from certain FDA application fees.\nIMM-1-104 was earlier granted the FDA’s Fast Track designation in the United States for the treatment of first- and second-line pancreatic cancer.\nYear to date, shares of Immuneering have plunged 68.6% compared with the industry’s decrease of 1.8%.\nImage Source: Zacks Investment Research\nRecent Developments Related to IMRX's IMM-1-104\nLast month, the company announced positive early response data from the first five patients of an ongoing early to mid-stage study evaluating IMM-1-104 combined with chemotherapy (modified gemcitabine/nab-paclitaxel) in first-line pancreatic cancer.\nIMM-1-104, an investigational RAS medication, is being evaluated in the phase I/IIa study in patients with advanced solid tumors harboring RAS mutations.\nA phase IIa study is evaluating the 320mg dose of IMM-1-104 as a monotherapy and in combination with two different chemotherapy regimens to treat pancreatic cancer. The phase IIa portion is also evaluating IMM-1-104 as monotherapy for non-small cell lung cancer and melanoma in different treatment arms.\nThe combination regimen of IMM-1-104 and modified gemcitabine/nab-paclitaxel was also overall well tolerated by the pancreatic cancer patients in the phase IIa portion of the study with a consistent safety profile for both therapeutics.\nInitial data from at least one additional arm of the phase IIa portion of the early to mid-stage study is expected by the end of 2024.\nBesides IMM-1-104, Immuneering has another pipeline candidate, IMM-6-415, which is being evaluated in a separate phase I/IIa study in patients with advanced solid tumors harboring RAS or RAF mutations.\nIn the absence of an approved product, pipeline development remains in key focus for the company.\nIMRX's Zack Rank & Stocks to Consider\nImmuneering currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. ANIP, Voyager Therapeutics, Inc. VYGR and Alnylam Pharmaceuticals, Inc. ALNY, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have moved up from $4.69 to $4.81. Earnings per share estimates for 2025 have improved from $5.37 to $5.86. Year to date, shares of ANIP have increased 6.2%.\nANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.\nIn the past 60 days, estimates for Voyager Therapeutics’ 2024 loss per share have narrowed from $1.47 to $1.44. Loss per share estimates for 2025 have narrowed from $1.95 to $1.94. Year to date, shares of VYGR have declined 18.8%.\nVYGR’s earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 104.33%.\nIn the past 60 days, estimates for Alnylam’s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per share estimates for 2025 have narrowed from 34 cents to 26 cents. Year to date, shares of ALNY have rallied 50.2%.\nALNY’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAlnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report\nANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report\nVoyager Therapeutics, Inc. (VYGR) : Free Stock Analysis Report\nImmuneering Corporation (IMRX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476945329"}